-

11:16:53 PM

ATHE Stock News

ATHE - Alterity Therapeutics Ltd

11/07/22 10:25 AM

Nasdaq : ATHE

Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation from

RHEA-AI

very negative

10/28/22 7:25 AM

Nasdaq : ATHE

Appendix 4C - Q1 FY23 Quarterly Cash Flow Report

First patient dosed in Phase 2 clinical trial for ATH434 in New Zealand, trial opens in Europe and Australia Approval of Investigational New Drug application by FDA to bring the Phase 2 clinical trial to the United States Data from bioMUSE study provides a quantitative measurement of MSA

RHEA-AI

positive

10/26/22 7:25 AM

Nasdaq : ATHE

Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation from

RHEA-AI

neutral

10/13/22 10:25 AM

Nasdaq : ATHE

clinical trial

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying

RHEA-AI

neutral

09/26/22 7:25 AM

Nasdaq : ATHE

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)

RHEA-AI

neutral

09/20/22 7:25 AM

Nasdaq : ATHE

fda approval

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying

RHEA-AI

neutral

08/25/22 7:25 AM

Nasdaq : ATHE

clinical trial

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease

RHEA-AI

neutral

07/22/22 7:25 AM

Nasdaq : ATHE

Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report

Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins Regulatory approval from the U.K. and Italian regulatory agencies to proceed with the Phase 2 trial A$4.1 million R&D Tax Incentive Scheme refund Cash balance on 30 June 2022 of A$34.8M MELBOURNE, Australia and

RHEA-AI

very positive

07/06/22 11:00 AM

Nasdaq : ATHE

clinical trial

Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first patient has been

RHEA-AI

neutral

06/23/22 11:00 AM

Nasdaq : ATHE

clinical trial

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the Italian Medicines

RHEA-AI

neutral